1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Enfermedades Infecciosas

Enfermedades Infecciosas

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Fortún J, Navas E.

    Latent tuberculosis infection: approach and therapeutic schemes

    REVISTA ESPANOLA DE QUIMIOTERAPIA . 35: 94-96. Nº de citas: 3

    [doi:10.37201/req/s03.20.2022]

  • Meca-Lallana JE, Fernández-Prada M, García Vázquez E, Moreno Guillén S, Otero Romero S, Rus Hidalgo M, Villar Guimerans LM, Eichau Madueño S, Fernández Fernández Ó, Izquierdo Ayuso G, Álvarez Cermeño JC, Arnal García C, Arroyo González R, Brieva Ruiz L, Calles Hernández C, García Merino A, González Plata M, Hernández Pérez MÁ, Moral Torres E, Olascoaga Urtaza J, Oliva-Nacarino P, Oreja-Guevara C, Ortiz Castillo R, Oterino A, Prieto González JM, Ramió-Torrentá L, Rodríguez-Antigüedad A, Saiz A, Tintoré M, Montalbán Gairin X.

    Consensus statement on the use of alemtuzumab in daily clinical practice in Spain.

    Neurologia . 37(8): 615-630. Nº de citas: 1

    [doi:10.1016/j.nrleng.2019.11.001]

  • Sánchez-Conde M, Vizcarra P, Pérez-García JM, Gion M, Martialay MP, Taboada J, Alonso-Fernández A, Sampayo-Cordero M, Malfettone A, Tena I, Torre S, Llombart-Cussac A, Cortés J.

    Pembrolizumab in combination with tocilizumab in high-risk hospitalized COVID-19 patients (COPERNICO): A randomized proof-of-concept phase II study.

    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES . 123: 97-103. Nº de citas: 4

    [doi:10.1016/j.ijid.2022.08.007]

  • Espindola R, Vella V, Benito N, Mur I, Tedeschi S, Rossi N, Hendriks JGE, Sorlí L, Murillo O, Scarborough M, Scarborough C, Kluytmans J, Ferrari MC, Pletz MW, Mcnamara I, Escudero-Sanchez R, Arvieux C, Batailler C, Dauchy FA, Liu WY, Lora-Tamayo J, Praena J, Ustianowski A, Cinconze E, Pellegrini M, Bagnoli F, Rodríguez-Baño J, Del Toro MD.

    Preoperative and perioperative risk factors, and risk score development for prosthetic joint infection due to Staphylococcus aureus: a multinational matched case-control study

    CLINICAL MICROBIOLOGY AND INFECTION . 28(10): 1359-1366. Nº de citas: 4

    [doi:10.1016/j.cmi.2022.05.010]

  • Meca-Lallana JE, Fernández-Prada M, García Vázquez E, Moreno Guillén S, Otero Romero S, Rus Hidalgo M, Villar Guimerans LM, Eichau Madueño S, Fernández Fernández Ó, Izquierdo Ayuso G, Álvarez Cermeño JC, Arnal García C, Arroyo González R, Brieva Ruiz L, Calles Hernández C, García Merino A, González Platas M, Hernández Pérez MÁ, Moral Torres E, Olascoaga Urtaza J, Oliva-Nacarino P, Oreja-Guevara C, Ortiz Castillo R, Oterino A, Prieto González JM, Ramió-Torrentá L, Rodríguez-Antigüedad A, Saiz A, Tintoré M, Montalbán Gairin X.

    Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    NEUROLOGIA . 37(8): 615-630. Nº de citas: 2

    [doi:10.1016/j.nrl.2019.11.003]

  • Royo-Cebrecos C, Laporte-Amargós J, Peña M, Ruiz-Camps I, Puerta-Alcalde P, Abdala E, Oltolini C, Akova M, Montejo M, Mikulska M, Martín-Dávila P, Herrera F, Gasch O, Drgona L, Morales HMP, Brunel AS, García E, Isler B, Kern WV, Palacios-Baena ZR, de la Calle GM, Montero MM, Kanj SS, Sipahi OR, Calik S, Márquez-Gómez I, Marin JI, Gomes MZR, Hemmatti P, Araos R, Peghin M, Del Pozo JL, Yáñez L, Tilley R, Manzur A, Novo A, Carratalà J, Gudiol C.

    Pseudomonas aeruginosa Bloodstream Infections in Patients with Cancer: Differences between Patients with Hematological Malignancies and Solid Tumors.

    PATHOGENS . 11(10): .

    [doi:10.3390/pathogens11101132]

  • Torres-Fernandez D, Jiménez de Ory S, Fortuny C, Sainz T, Falcón D, Bernal E, Jiménez MC, Vilasaró MN, Epalza C, Navarro M, Ramos JT, Holguín Á, Prieto L.

    Integrase inhibitors in children and adolescents: clinical use and resistance

    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY . 77(10): 2784-2792. Nº de citas: 1

    [doi:10.1093/jac/dkac259]

  • Madrid-Elena N, Serrano-Villar S, Gutiérrez C, Sastre B, Morín M, Luna L, Martín L, Santoyo-López J, López-Huertas MR, Moreno E, García-Bermejo ML, Moreno-Pelayo MÁ, Moreno S.

    Selective miRNA inhibition in CD8(+) cytotoxic T lymphocytes enhances HIV-1 specific cytotoxic responses.

    Frontiers in immunology . 13: 998368-998368.

    [doi:10.3389/fimmu.2022.998368]

  • Vallejo A, Vizcarra P, Martín-Hondarza A, Gómez-Maldonado S, Haemmerle J, Velasco H, Casado JL.

    Impact of SARS-CoV-2-specific memory B cells on the immune response after mRNA-based Comirnaty vaccine in seronegative health care workers

    FRONTIERS IN MICROBIOLOGY . 13: 1002748-1002748.

    [doi:10.3389/fmicb.2022.1002748]

  • Norman FF, Treviño-Maruri B, Giardín JMR, Gullón-Peña B, Salvador F, Serre N, Díaz-Menéndez M, Calabuig E, Rodriguez-Guardado A, Lombide I, Pérez-Ayala A, Torrús D, Goikoetxea J, García-Rodriguez M, Pérez-Molina JA.

    Trends in Imported Malaria during the COVID-19 pandemic, Spain (+Redivi Collaborative Network).

    JOURNAL OF TRAVEL MEDICINE . 29(6): .

    [doi:10.1093/jtm/taac083]

  • Álvarez H, Rava M, Martínez C, Portilla J, Peraire J, Rivero A, Cervero M, Mariño A, Poveda E, Llibre JM.

    Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort.

    HIV MEDICINE . 23(8): 825-836.

    [doi:10.1111/hiv.13265]

  • Corbacho-Loarte MD, Crespillo-Andújar C, Chamorro-Tojeiro S, Norman F, Pérez-Molina JA, Martín O, Rubio JM, Gullón-Peña B, López-Vélez R, Monge-Maillo B.

    Screening of imported malaria infection in asymptomatic migrants from Sub-Saharan Africa: A retrospective analysis of a 2010-2019 cohort

    TRAVEL MEDICINE AND INFECTIOUS DISEASE . 49: 102411-102411. Nº de citas: 3

    [doi:10.1016/j.tmaid.2022.102411]

  • Busca C, Arias P, Sánchez-Conde M, Rico M, Montejano R, Martín-Carbonero L, Valencia E, Moreno V, Bernardino JI, Olveira A, Abadía M, González-García J, Montes ML.

    Genetic variants associated with steatohepatitis and liver fibrosis in HIV-infected patients with NAFLD.

    FRONTIERS IN PHARMACOLOGY . 13: 905126-905126.

    [doi:10.3389/fphar.2022.905126]

  • Perez Stachowski J, Rial Crestelo D, Moreno Zamora A, Cabello N, Ryan P, Espinosa Aguilera N, Bisbal O, Vivancos Gallego MJ, Nuñez MJ, Troya J, Dominguez M, Sierra JO.

    Use of Tenofovir Alafenamide/Emtricitabine/Elvitegravir-Cobicistat in HIV-Naive Patients with Advanced Disease: GENIS Study.

    Journal Of Clinical Medicine . 11(17): .

    [doi:10.3390/jcm11174994]

  • Hernández-Sampelayo T, Gómez-Pavón J, González Del Castillo J, Martín-Delgado MC, Martín Sánchez FJ, Martínez-Sellés M, Molero García JM, Moreno Guillén S, Rodríguez-Artalejo FJ, Ruiz-Galiana J, Cantón R, De Lucas Ramos P, García-Botella A, García-Lledó A, Calvo Rey P, Bouza E.

    COVID in Pediatric Age: an opinion paper.

    REVISTA ESPANOLA DE QUIMIOTERAPIA . 35(4): 333-343. Nº de citas: 1

    [doi:10.37201/req/012.2022]

  • Vizcarra P, Rosillo M, del Rey JM, Moreno A, Vivancos MJ, Casado JL.

    Unravelling hip-spine bone mineral density discordance in people living with HIV.

    JOURNAL OF BONE AND MINERAL METABOLISM . 40(6): 990-997.

    [doi:10.1007/s00774-022-01365-z]

  • Casado JL, Vizcarra P, Haemmerle J, Velasco H, Martín-Hondarza A, Rodríguez-Domínguez MJ, Velasco T, Martín S, Romero-Hernández B, Fernández-Escribano M, Vallejo A.

    Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2.

    Vaccine: X . 11: 100165-100165. Nº de citas: 3

    [doi:10.1016/j.jvacx.2022.100165]

  • Fanciulli C, Berenguer J, Busca C, Vivancos MJ, Téllez MJ, Domínguez L, Domingo P, Navarro J, Santos J, Iribarren JA, Morano L, Artero A, Moreno J, Rivero-Román A, Santos I, Giner L, Armiñanzas C, Montero M, Manzardo C, Cifuentes C, García C, Galindo MJ, Ferrero OL, Sanz J, de la Fuente B, Rodríguez C, Gaspar G, Pérez L, Losa JE, Force L, Veloso S, Martínez-Alfaro E, Jarrín I, De Miguel M, González Garcia J.

    Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019

    HIV MEDICINE . 23(7): 705-716. Nº de citas: 9

    [doi:10.1111/hiv.13229]